AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25001267
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group received a 20 stipend monthly and engaged in social/leisure activities for 2 hours weekly over a 9-month period.
Trial: 25001267
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received a 20 monthly stipend and engaged in a weekly social/leisure activity.
Trial: 10692984
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day and 150 mg/day
Trial: 8741209
Drug: Berberine 200
RxNorm normalized name: Dihydroberberine 200 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine 200 mg
Trial: 8741209
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid 2 g
Trial: 8741209
Drug: Tetracycline (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (single dose)
Trial: 1914797
Drug: Soluble human
RxNorm normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble human insulin (Actrapid HM U-100)
Trial: 7121133
Drug: Mexiletine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (200 mg three times per day)
Trial: 31278907
Drug: Nasal cannula
RxNorm normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannula group (O2 [2 L/minute] via nasal cannula)
Trial: 22515513
Drug: HD203 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD203 (25 mg/mL, administered subcutaneously)
Trial: 22515513
Drug: Enbrel® (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enbrel® (25 mg/mL, administered subcutaneously)
Trial: 25961781
Drug: BMS-820836 flexible
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-820836 flexible dose (0.5-2 mg/d)
Trial: 25961781
Drug: BMS-820836 fixed
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BMS-820836 fixed dose (1 mg/d or greater)
Trial: 25961781
Drug: BMS-820836 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-820836 (2 mg/d)
Trial: 19298914
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and glycoprotein IIb/IIIa inhibitors
Trial: 3289675
Drug: terodiline 25
RxNorm normalized name: terodiline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terodiline 25 mg bd
Trial: 3289675
Drug: emepronium bromide
RxNorm normalized name: emepronium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emepronium bromide 200 mg tds
Trial: 25710507
Drug: CXL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXL treatment (0.1% riboflavin drops and UV-A irradiation at 365 nm for 30 minutes)
Trial: 23787458
Drug: CXL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CXL treatment
Trial: 21345638
Drug: Antibody persistence
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody persistence evaluation
Trial: 16441800
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of dexamethasone
Trial: 10811673
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m(2) given as a 1‐hour intravenous infusion every 3 weeks
Trial: 1457907
Drug: Quinine 325
RxNorm normalized name: quinine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine 325 mg at bedtime
Trial: 28902105
Drug: Intra-articular Corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular Corticosteroid Injection (ICI)
Trial: 1444724
Drug: Caffeine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (both doses)
Trial: 20613496
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of telmisartan (80 mg) and amlodipine (10 mg)
Trial: 7843758
Drug: Amlodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (10 mg)
Trial: 20399994
Drug: Rosuvastatin 5
RxNorm normalized name: rosuvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 5 mg
Trial: 18042475
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg (fed state)
Trial: 15122133
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine PCA infusion at 5 mL per hour with a bolus dose of 2 mL at a 15-minute lockout period (group I)
Trial: 15122133
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion under the same conditions (group II)
Trial: 9619811
Drug: Willingness to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willingness to participate in a randomized vaccine efficacy trial
Trial: 9619811
Drug: Baseline knowledge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline knowledge of vaccine trial concepts
Trial: 326495
Drug: Indapamide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (2.5 mg to 5 mg)
Trial: 28068596
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus omega 3
Trial: 21204889
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with VCE supplementation (vitamin C 500 mg tablet and vitamin E 400 mg gelatin capsule)
Trial: 21204889
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (5‐fluorouracil 500 mg/m(2) i.v. day 1, doxorubicin 50 mg/m(2) i.v. day 1, cyclophosphamide 500 mg/m(2) i.v. day 1, every 3 weeks for six cycles)
Trial: 17445266
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg 5-ALA via inhalation 1, 2, 3, 4 or 6 hours before bronchoscopy
Trial: 17445266
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg 5-ALA via inhalation
Trial: 17445266
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg 5-ALA via inhalation 160 min prior to bronchoscopy
Trial: 15610951
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose transdermal nicotine patch (14 or 21 mg)
Trial: 2357862
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg caffeine plus 75 mg phenylpropanolamine
Trial: 2357862
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg caffeine alone
Trial: 2357862
Drug: phenylpropanolamine-caffeine combination
RxNorm normalized name: caffeine / phenylpropanolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phenylpropanolamine-caffeine combination
Trial: 25589326
Drug: Albendazole plus
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole plus oxantel pamoate (400 mg + 20 mg/kg)
Trial: 25589326
Drug: Albendazole plus
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole plus ivermectin (400 mg + 200 μg/kg)
Trial: 25589326
Drug: Mebendazole alone
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole alone (500 mg)
Trial: 25589326
Drug: Albendazole plus
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole plus mebendazole (400 mg + 500 mg)
Trial: 22967344
Drug: Acarbose 50
RxNorm normalized name: acarbose 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg added to insulin treatment
Trial: 22967344
Drug: Preprandial ultra-short
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preprandial ultra-short effect insulin and long-acting insulin before bedtime (Control group)
Trial: 17986032
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam 0.5 mg.kg (‐1)
Trial: 17986032
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine 4 microg.kg (‐1)
Trial: 9456288
Drug: celiprolol (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celiprolol (200-400 mg daily)
Trial: 2119168
Drug: sorbinil (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorbinil (250 mg daily for 3 years)
Trial: 7435677
Drug: Amitriptyline alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline alone, up to a maximum dose of 300 mg/day
Trial: 7435677
Drug: Tranylcypromine alone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranylcypromine alone, up to a maximum dose of 40 mg/day
Trial: 7435677
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amitriptyline (up to 150 mg/day) and tranylcypromine (up to 20 mg/day)
Trial: 16877627
Drug: Randomised controlled
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised controlled trial (RCT) for a new drug
Trial: 7856175
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg/day
Trial: 10852357
Drug: 12-month treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month treatment programs
Trial: 10852357
Drug: Longer residential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer residential treatment program
Trial: 31897315
Drug: Lignocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine spray (1 puff, 1.5 mg/kg)
Trial: 31897315
Drug: Nitroglycerin spray
RxNorm normalized name: nitroglycerin Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin spray (1 puff, 400 μg)
Trial: 11423812
Drug: Sequential presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential presentation format
Trial: 1722512
Drug: Parenteral gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral gold therapy
Trial: 30761786
Drug: Canephron N
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canephron N (2 tablets 3 times daily for 30 days)
Trial: 30761786
Drug: Ciprofloxacin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (0.5 g twice daily for 3 days)
Trial: 25382328
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose atorvastatin 80 mg followed by 20 mg/d (LD group)
Trial: 23519529
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: 10 mg of lutein, 1 mg of zeaxanthin, 100 mg of docosahexaenoic acid, and 30 mg of eicosapentaenoic acid daily
Trial: 23519529
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Double the dose of Group 1
Trial: 20943956
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Zn/d as Zn sulfate
Trial: 20943956
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Zn/d as Zn sulfate
Trial: 30383205
Drug: Intravitreal lampalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravitreal lampalizumab treatment
Trial: 8941107
Drug: Metoprolol at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol at 125 to 150 mg/d
Trial: 27267854
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate + prednisone (1,000 mg/d + 5 mg/d)
Trial: 27267854
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate + exemestane (1,000 mg/d + 25 mg/d)
Trial: 24796463
Drug: Trastuzumab administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab administered sequentially with anthracycline
Trial: 18771049
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg twice daily of Phase III formulation
Trial: 18771049
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg twice daily of Phase III formulation
Trial: 18771049
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg twice daily of Phase II formulation
Trial: 12176916
Drug: Intravenous cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclosporin A (CsA)
Trial: 10207508
Drug: GH administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH administration (i.v. GH bolus)
Trial: 10207508
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion with GH administration
Trial: 10207508
Drug: Insulin induced
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin induced hypoglycemia in GH-deficient patients
Trial: 7598298
Drug: Twice-weekly regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly regimen of sulfadiazine (500 mg four times per day) plus pyrimethamine (25 mg) plus folinic acid (15 mg)
Trial: 7598298
Drug: Daily regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily regimen of sulfadiazine (500 mg four times per day) plus pyrimethamine (25 mg) plus folinic acid (15 mg)
Trial: 28986029
Drug: Daily regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily regimen
Trial: 2184706
Drug: Topical TAC
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TAC (0.5% tetracaine, 1:2,000 adrenalin, 11.8% cocaine)
Trial: 11188564
Drug: Intradermal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal lidocaine
Trial: 30231866
Drug: Levothyroxine 25
RxNorm normalized name: LEVOTHYROXINE 25MCG/ML ORAL SOLN UD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine 25 or 50 micrograms daily
Trial: 10774589
Drug: Atevirdine (dose-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atevirdine (dose-adjusted to achieve plasma trough concentrations of 5-10 microM) and zidovudine (200 mg every 8 h) for 12 weeks (ACTG 199)
Trial: 10774589
Drug: Atevirdine monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atevirdine monotherapy with doses adjusted to achieve targeted trough plasma concentration ranges (5-13, 14-22, and 23-31 microM) for 12 weeks (ACTG 187)
Trial: 6743720
Drug: Naloxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2 mg/kg iv bolus infusion)
Trial: 29424441
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg IV iron isomaltoside infusion
Trial: 26710216
Drug: Ketorolac 60
RxNorm normalized name: ketorolac 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 60 mg (group K)
Trial: 23026514
Drug: High thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High thiamine diet (2.8 mg/day)
Trial: 23026514
Drug: Adequate thiamine
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adequate thiamine diet (1.1 mg/day)
Trial: 20040884
Drug: Musculoskeletal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Musculoskeletal therapy and physical therapy prior to weight management program
Trial: 12422590
Drug: Azithromycin 20
RxNorm normalized name: azithromycin 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 20 mg/kg/day for the first day followed by 10 mg/kg/day for a further four days
Trial: 10028084
Drug: Clarithromycin plus
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin plus clofazimine with additional antimycobacterial drugs (ethambutol, ciprofloxacin, amikacin, rifabutin)
Trial: 6616153
Drug: L-phenylalanine mustard
RxNorm normalized name: L-Phenylalanine mustard
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-phenylalanine mustard (L-PAM) as adjuvant chemotherapy
Trial: 6616153
Drug: Routine sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine sequential chest radiography
Trial: 30906874
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment
Trial: 25683747
Drug: 0.3 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g/kg glucose
Trial: 25683747
Drug: 0.2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g/kg glucose
Trial: 24080099
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus supervised exercise therapy
Trial: 16029398
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal ketamine (50 mg)
Trial: 2068474
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of aztreonam and cloxacillin/oxacillin
Trial: 2068474
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tobramycin and a cephalosporin
Trial: 6683538
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg calcium dobesilate
Trial: 6683538
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg calcium dobesilate
Trial: 6683538
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg calcium dobesilate
Trial: 7760988
Drug: Minaprine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minaprine (200 mg)
Trial: 7760988
Drug: Imipramine (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (50, 75, 100 mg)
Trial: 2397553
Drug: Modified Xiao‐Jin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Xiao‐Jin Pills (MXJP)
Trial: 81155
Drug: Dihydrocodeine tartrate
RxNorm normalized name: Dihydrocodeine tartrate
DrugBank: Dihydrocodeine (DB01551)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydrocodeine tartrate (30 mg)
Trial: 30833647
Drug: Capecitabine for
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine for 6 months (2500 mg/m2/day for 14 out of 21 days)
Trial: 30833647
Drug: Capecitabine for
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine for 12 months (2500 mg/m2/day for 14 out of 21 days)
Trial: 21837551
Drug: Process Assessment
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Process Assessment of the Learner (PAL) lesson plans, specifically Lesson Sets 4 and 7, conducted via small groups (3-6 students) twice a week for 12 weeks.
Trial: 9039714
Drug: Continuous and
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous and intermittent use of GTN patches
Trial: 9039714
Drug: Changing to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changing to a different transdermal system
Trial: 3882216
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment only (S-group)
Trial: 24909206
Drug: Closed-loop therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop therapy with meal announcement
Trial: 26072052
Drug: Conventional pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pump therapy
Trial: 17391167
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and pioglitazone 30 mg daily
Trial: 15713724
Drug: Oral Testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Testosterone (T) 200, 400, or 800 mg in sesame oil
Trial: 15713724
Drug: Oral Testosterone
RxNorm normalized name: testosterone Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Testosterone Enanthate (TE) 200, 400, or 800 mg in sesame oil